Issues
-
Cover Image
Cover Image
The efficacy of CAR T-cell therapy against solid tumors is limited by insufficient infiltration of the tumor by CAR T cells. Using models of mesothelioma and non–small cell lung cancer, Quach, Skovgard, and Villena-Vargas et al. show that a nonablative dose of tumor-targeted radiation administered prior to systemic mesothelin-targeted CAR T-cell therapy enhances tumor accumulation of CAR T cells. This occurs because the radiation induces tumor secretion of chemokines and upregulation of chemokine-receptor expression in tumor-infiltrating CAR T cells, which also exhibit enhanced proliferation, functional persistence, and antitumor efficacy. The study data highlight the clinical potential of sequential therapy with tumor-targeted radiation followed by systemic administration of CAR T cells. Read more in this issue on page 1314. Original image from Fig. 6A. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We're Reading
Editorial
In the Spotlight
Rising Stars in Cancer Immunology
Research Articles
Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy
Insufficient infiltration of solid tumors limits CAR T-cell efficacy. The authors show nonablative, tumor-targeted radiation generates a tumor-secreted chemokine gradient that facilitates CAR T-cell chemotaxis; early and higher tumor infiltration; and superior proliferation, functional persistence, and antitumor efficacy.
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance
Data demonstrate that combining CD40 activation, CSF1R blockade, and PD-1 inhibition can overcome immune checkpoint inhibitor resistance in melanoma. Acute treatment responses are CD40 agonist–driven and enhance the function of IL12-secreting DCs to recruit activated T cells.
Glioblastoma Vascular Plasticity Limits Effector T-cell Infiltration and Is Blocked by cAMP Activation
The authors show the cAMP activator ibudilast normalizes the tumor vasculature and improves the therapeutic efficacy of anti–PD-1 in preclinical glioblastoma models. The data uncover a role for glioblastoma-derived endothelial cells in modulating the tumor immune microenvironment.
ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers
ANXA1 promotes cancer immune escape by transcriptionally upregulating PD-L1 in cancer cells and could be a potential target for immunotherapy. Evaluating both ANXA1 and PD-L1 could serve as a predictor for efficacy and prognosis of patients receiving immunotherapy.
CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression
The authors show BMSCs induce MM-cell secretion of CXCL10, recruiting γδ T cells to BM. Hypoxia in the BM activates a SRC-3/RORγt/IL17 axis in the γδ T cells that can be targeted to reduce immunosuppression and MM progression.
Cholesterol Efflux Drives the Generation of Immunosuppressive Macrophages to Promote the Progression of Human Hepatocellular Carcinoma
The tumor microenvironment cooperatively reprograms cholesterol metabolism in monocytes, which promotes generation of semi-mature macrophages and hepatocellular carcinoma progression. Selectively modulating cholesterol metabolism in specific cell subsets within tumors may serve as an effective strategy for cancer therapy.
Ncoa2 Promotes CD8+ T cell–Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function
Ncoa2 is identified as a critical regulator for boosting mitochondrial activity during CD8+ T-cell activation via upregulation of PGC-1α expression. The data highlight the potential of targeting Ncoa2 as a cancer therapy.
Tumor Cell–Intrinsic c-Myb Upregulation Stimulates Antitumor Immunity in a Murine Colorectal Cancer Model
The authors show c-Myb in tumor cells induces expression of immune-related genes, resulting in immunomodulation and tumor growth inhibition. The findings provide a possible mechanistic explanation for the observed better prognosis in cancer patients with higher c-Myb expression.
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds